| Today’s Big NewsFeb 26, 2025 |
| By James Waldron Eikon Therapeutics is no stranger to eye-catching funding rounds, and the cancer-focused biotech has continued this trend with a $350.7 million series D to fuel its various clinical trials. |
|
|
|
By Nick Paul Taylor AstraZeneca has advanced its push to make camizestrant a blockbuster, reporting a phase 3 win for the oral SERD at an interim analysis. The trial hit on progression-free survival, its primary endpoint, but is yet to show patients live longer on the drug candidate. |
By Gabrielle Masson Eli Lilly has acquired Organovo’s lead asset, a clinical FXR agonist designed to treat inflammatory bowel disease, in a deal worth up to $50 million in biobucks. Since the buy was announced, Organovo’s stock has skyrocketed 244%. |
Sponsored by Sciensus Avoid common pitfalls in EU orphan drug market access—learn how local expertise can help navigate pricing, reimbursement, and regulatory hurdles. |
|
With so many options, finding the ideal test system can be a challenge, so BioIVT compiled a guide outlining the differences with recommendations for different studies, tips on their use and more... Download Now >> 
|
|
By James Waldron The deal will see HBM Alpha Therapeutics, which was formed around Harbour’s antibody expertise, transfer the global rights outside of China for a corticotropin-releasing hormone therapy to an unnamed “business partner.” |
Sponsored by Fortrea Fortrea's CTO discusses AI's expanding role in clinical trials, from discovery to execution, and its potential to improve patient outcomes and diversity. |
By Nick Paul Taylor Alopexx is forging ahead with long-gestating plans to go public, updating IPO paperwork to fund trials of candidates including an infectious disease antibody that was once the focus of a $375 million deal with Sanofi. |
By James Waldron With the latest hopes of licensing its hypertension drug Tryvio falling through, Idorsia has moved to claw back $100 million in upcoming development costs from a separate licensing deal with Viatris. |
By Noah Tong Republican holdouts, who stated repeatedly they would not vote for the bill, ultimately opted to advance legislation which will require significant Medicaid cuts. |
By Kevin Dunleavy At a press conference in Washington, D.C. dubbed “Lilly in America,” the Indianapolis drugmaker said it will begin construction on four new production facilities in the U.S. The effort will more than double what the company has earmarked for domestic drug manufacturing since 2020, bringing the total outlay to more than $50 billion. |
Fierce podcasts Don’t miss an episode |
| This week on "The Top Line," we dive into several of the biggest failures in clinical-stage drug development last year and discuss what the biopharma industry can learn from these setbacks. |
|
|---|
|
|
Whitepaper This paper reviews key developments in the oncology market during 2024 and outlines what they mean for the future. Presented by Blue Matter, strategic consultants in the life sciences |
| Submissions Open Early August |
|
|
| |
|
